Hepatitis A and hepatitis B vaccination responses in persons with chronic hepatitis C infections: A review of the evidence and current recommendations

Canadian Journal of Infectious Diseases and Medical Microbiology

Volumn 19, Issue 2, 2008, Pages 197-202

  Buxton, Jane A ^a,b   Kim, Jin Hee ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

Author keywords

Hepatitis A virus; Hepatitis B virus; Hepatitis C virus; Immunization; Vaccine efficacy

Indexed keywords

HEPATITIS A ANTIBODY; HEPATITIS A VACCINE; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B VACCINE;

DRUG EFFICACY; FOLLOW UP; GENOTYPE; HEALTH CARE ORGANIZATION; HEPATITIS A; HEPATITIS B; HEPATITIS C; HUMAN; LABORATORY TEST; LIVER CIRRHOSIS; PATIENT ATTITUDE; PRACTICE GUIDELINE; REVIEW; VACCINATION;

EID: 44449125241     PISSN: 17129532     EISSN: None     Source Type: Journal    
DOI: 10.1155/2008/410362     Document Type: Review

References (34)

1. Wu HX, Wu J, Wong T, et al. Enhanced surveillance of newly diagnosed hepatitis C virus infection in Canada, 1998 to 2004. Scand J Infect Dis 2006;38:482-9.
2. Vento S, Garofano T, Renzini C, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998;29;338:286-90.
3. Neilsen GA, Bodsworth NJ, Watts N. Response to hepatitis A vaccination in human immunodeficiency virus-infected and uninfected homosexual men. J Infect Dis 1997;176:1064-7.
4. Crespo J, Lozano JL, Carte B, de las Heras B, de la Cruz F, Pons-Romero F. Viral replication in patients with concomitant hepatitis B and C virus infections. Eur J Clin Microbiol Infect Dis 1997;16:445-51.
5. Zarski JP, Bonn B, Bastie A, et al. Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol 1998;28:27-33.
6. Tyndall MW, Lai C, Ishida T, Shannon K, Cook D, Kerr T. Continued high rates of HIV and hepatitis C transmission among a vulnerable community in Vancouver: The CHASE project. The 13th Annual Canadian Conference on HIV/AIDS Research Montreal, Quebec, May 13-16, 2004.
7. Patrick DM, Tyndall MW, Cornelisse PGA, et al. Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection. CMAJ 2001;165:889-95.
8. Pasricha N, Datta U, Chawla Y, et al. Poor responses to recombinant HBV vaccination in patients with HIV infection. Trop Gastroenterol 2005;26:178-82.
9. Corrao G, Calleri M, Zotti M, et al. Immune response to anti-HBV vaccination: Study of conditioning factors. Eur J Epidemiol 1988;4:492-6.
10. Yu AS, Cheung RC, Keeffe EB. Hepatitis B vaccines. Clin Liver Dis 2004;8:283-300.
11. Girndt M, Köhler H. Hepatitis B virus infection in hemodialysis patients. Semin Nephrol. 2002;22:340-50.
12. Wiedmann M, Liebert UG, Oesen U, et al. Decreased immunogenicity of recombinant hepatitis B vaccine in chronic hepatitis C. Hepatology 2000;31:230-4.
13. De Maria N, Idilman R, Colantoni A, Harig JM, Van Thiel DH. Antibody response to hepatitis B virus vaccination in individuals with hepatitis C virus infection. Hepatology 2000;32:444-5.
14. Keeffe EB, Iwarson S, McMahon BJ, et al. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatology 1998;27:881-6.
15. Lee SD, Chan CY, Yu MI, et al. Safety and mmunogenicity of inactivated hepatitis A vaccine in patients with chronic liver disease. J Med Virol 1997;52:215-8.
16. Strader DB, Wright T, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147-71. (Erratum in 2004;40:269).
17. Centers for Disease Control and Prevention. Prevention of Hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices, 〈http://www.cdc.gov/mmwr/preview/ mmwrhtml/rr5507a1.htm〉 (Version current at February 22, 2008).
18. National Advisory Committee on Immunization. Canadian Immunization Guide, 7th edn. Canadian Medical Association, 2006.
19. Lee SD, Chan CY, Yu MI, Lu RH, Chang FY, Lo KJ. Hepatitis B vaccination in patients with chronic hepatitis C. J Med Virol 1999;59:463-8.
20. De Maria N, Idilman R, Colantoni A, Van Thiel DH. Increased effective immunogenicity to high-dose and short-interval hepatitis B virus vaccination in individuals with chronic hepatitis without cirrhosis. J Viral Hepat 2001;8:372-6.
21. Idilman R, De MN, Colantoni A, Nadir A, Van Thiel DH. The effect of high dose and short interval HBV vaccination in individuals with chronic hepatitis C. Am J Gastroenterol 2002;97:435-9.
22. Mattos AA, Gomes EB, Tovo OV, Alexandre CO, Remião JO. Hepatitis B vaccine efficacy in patients with chronic liver disease by hepatitis C virus. Arq Gastroenterol 2004;41:180-4.
23. Chlabicz S, Grzeszczuk A, Lapinski TW. Hepatitis B vaccine immunogenicity in patients with chronic HCV infection at one year follow-up: The effect of interferon-alpha therapy. Med Sci Monit 2002:8:CR379-83.
24. Chlabicz S, Lapinski TW, Grzeszczuk A, Prokopowicz D. Four-year follow up of hepatitis C patients vaccinated against hepatitis B virus. World J Gastroenterol 2005;11:1798-801.
25. Elefsiniotis IS, Vezali E, Kampsoioras K, et al. Immunogenicity of recombinant hepatitis B vaccine in treatment-naive and treatment-experienced chronic hepatitis C patients: The effect of pegylated interferon plus ribavirin treatment. World J Gastroenterol 2006;12:4420-4.
26. Leroy V, Bourliere M, Durand M, et al. The antibody response to hepatitis B virus vaccination is negatively influenced by the hepatitis C virus viral load in patients with chronic hepatitis C: A case-control study. Eur J Gastroenterol Hepatol 2002;14:485-9.
27. Daryani NE, Nassiri-Toosi M, Rashidi A, Khodarahmi I. Immunogenicity of recombinant hepatitis B virus vaccine in patients with and without chronic hepatitis C virus infection: A case-control study. World J Gastroenterol 2007;13:294-8.
28. World Health Organization. Hepatitis B. 〈http://www.who.int/csr/ disease/hepatitis/HepatitisB_whocdscsrlyo2002_2.pdf〉 (Version current at February 22, 2008).
29. World Health Organization. Hepatitis C. 〈http://www.who.int/csr/ disease/hepatitis/Hepc.pdf〉 (Version current at February 22, 2008).
30. Centers for Disease Control and Prevention. Recommendations for prevention and control of Hepatitis C virus (HCV) infection and HCV-related chronic disease . 〈http://www.cdc.gov/mmwr/preview/mmwrhtml/00055154. htm〉 (Version current at February 22, 2008).
31. Centers for Disease Control and Prevention. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States. Recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: Immunization of adults. 〈http://www.cdc.gov/mmwR/PDF/rr/ rr5516.pdf〉 (Accessed November 1, 2007).
32. Van Damme P, Van Herck K. A review of the long-term protection after hepatitis A and B vaccination. Travel Med Infect Dis 2007;5:79-84.
33. Reiss G, Keeffe EB. Review article: Hepatitis vaccination in patients with chronic liver disease. Aliment Pharmacol Ther 2004;19:715-27.
34. Sherman M, Bain V, Villeneuve JP, et al. Management of viral hepatitis: A Canadian consensus conference, 2004. 〈http://www.hepatology.ca/cm/FileLib/ ViralHepatitisCanadianConsensus2004.pdf〉 (Version current at February 22, 2008).